News
The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...
TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback